Akari Therapeutics Plc (AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Market Cap
$20K
Revenue
$0
P/E Ratio
N/A
P/B Ratio
0.00
D/E Ratio
0.15
Dividend Yield
0.00%
Updated: June 7 at 24:02:05